Drugs / MarzAA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04072237 | Sep 2019 → Apr 2020 | hemophilia A, hemophilia B | Catalyst Biosciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04548791 | May → Nov 2021 | Glanzmann thrombasthenia, factor VII deficiency, hemophilia A | Catalyst Biosciences | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04489537 | May → Nov 2021 | hemophilia A, hemophilia B | Catalyst Biosciences | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MarzAA | “Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes” NCT04548791 ↗ |
| Known as | marzeptacog alfa [activated] | “MarzAA (marzeptacog alfa [activated])” NCT04072237 ↗ |
| Modality | Protein / enzyme biologic | “MarzAA (Coagulation Factor VIIa variant)” NCT04072237 ↗ |
| Route | Intravenous | “18 µg/kg intravenously” NCT04072237 ↗ |